1. |
Can statins operate as neuroprotective agents? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1305,
2001,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
2. |
Emerging treatment options for bipolar disorder |
|
Inpharma Weekly,
Volume &NA;,
Issue 1305,
2001,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
3. |
Micronised progesterone: greater QOL in postmenopausal women |
|
Inpharma Weekly,
Volume &NA;,
Issue 1305,
2001,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
4. |
Linezolid low-cost option for cellulitis in the UK |
|
Inpharma Weekly,
Volume &NA;,
Issue 1305,
2001,
Page 5-6
Pamela Hunter,
Preview
|
|
摘要:
Linezolid is a new oxazolidinone antibacterial agent with activity against many strains of Gram-positive bacteria that are resistant to numerous commonly used antibacterial agents. At present, the acquisition cost of linezolid is slightly greater than that of flucloxacillin or vancomycin, but this can be offset by increased efficacy, resulting in a reduction in the length of stay in hospital. At the 22nd International Congress of Chemotherapy [Amsterdam, The Netherlands; July 2001], a poster presentation showed that when linezolid was used to treat patients with cellulitis, it proved more cost effective than either vancomycin or flucloxacillin.
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
5. |
Enoxaparin sodium cost effective for VTE prevention |
|
Inpharma Weekly,
Volume &NA;,
Issue 1305,
2001,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
6. |
Rituximab may be beneficial in chronic refractory ITP |
|
Inpharma Weekly,
Volume &NA;,
Issue 1305,
2001,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1305,
2001,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
8. |
Levodopa + physiotherapy improves motor recovery in stroke |
|
Inpharma Weekly,
Volume &NA;,
Issue 1305,
2001,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1305,
2001,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
10. |
HERO-2: bivalirudin benefits patients with MI |
|
Inpharma Weekly,
Volume &NA;,
Issue 1305,
2001,
Page 11-12
Carmen Innes,
Preview
|
|
摘要:
Bivalirudin, a direct-acting thrombin inhibitor, has potential in reducing mortality and second myocardial infarction (MI) in patients who have already had an MI and are receiving fibrinolysis, according to results of the HERO-2*study, released at the 23rd Congress of the European Society of Cardiology [Stockholm, Sweden; September 2001]. Bivalirudin ['Hirulog', 'Angiomax'] decreased the combined incidence of mortality and investigator-reported MI at 30 days by 1.3%, compared to unfractionated heparin (12.9vs14.2%; p = 0.023). In addition, the combined incidence of mortality, reinfarction or nonfatal disabling stroke was also significantly lower in patients who received bivalirudin, compared with those receiving unfractionated heparin, resulting in 11 fewer events per 1000 patients randomised to receive bivalirudin. The primary endpoint, reduction in mortality at 30 days, was lower in patients treated with bivalirudin than in those treated with unfractionated heparin, but the between-group difference was not significant.
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|